JP4686634B2 - 肝細胞成長因子（ｈｇｆ）結合蛋白質 - Google Patents

肝細胞成長因子（ｈｇｆ）結合蛋白質 Download PDF

Info

Publication number
JP4686634B2
JP4686634B2 JP2009513295A JP2009513295A JP4686634B2 JP 4686634 B2 JP4686634 B2 JP 4686634B2 JP 2009513295 A JP2009513295 A JP 2009513295A JP 2009513295 A JP2009513295 A JP 2009513295A JP 4686634 B2 JP4686634 B2 JP 4686634B2
Authority
JP
Japan
Prior art keywords
seq
sequence
variable region
antibody
hgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009513295A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009539347A5 (enExample
JP2009539347A (ja
Inventor
ウィリアム エム． ウィンストン，
エス． カーク ライト，
メイ ハン，
リン ブレオー，
チエ リン，
ビジャン エテマド−ギルバートソン，
クリスティン クヌーエル，
ジェノ ギュリス，
アーノルド ホーウィッツ，
Original Assignee
アベオ ファーマシューティカルズ， インコーポレイテッド
ゾーマ テクノロジー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アベオ ファーマシューティカルズ， インコーポレイテッド, ゾーマ テクノロジー リミテッド filed Critical アベオ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2009539347A publication Critical patent/JP2009539347A/ja
Publication of JP2009539347A5 publication Critical patent/JP2009539347A5/ja
Application granted granted Critical
Publication of JP4686634B2 publication Critical patent/JP4686634B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
JP2009513295A 2006-06-02 2007-06-01 肝細胞成長因子（ｈｇｆ）結合蛋白質 Active JP4686634B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US81071406P 2006-06-02 2006-06-02
US60/810,714 2006-06-02
US86050906P 2006-11-21 2006-11-21
US60/860,509 2006-11-21
PCT/US2007/012939 WO2007143090A2 (en) 2006-06-02 2007-06-01 Hepatocyte growth factor (hgf) binding proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010294222A Division JP2011072318A (ja) 2006-06-02 2010-12-28 肝細胞成長因子（ｈｇｆ）結合蛋白質

Publications (3)

Publication Number Publication Date
JP2009539347A JP2009539347A (ja) 2009-11-19
JP2009539347A5 JP2009539347A5 (enExample) 2011-02-24
JP4686634B2 true JP4686634B2 (ja) 2011-05-25

Family

ID=38802077

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009513295A Active JP4686634B2 (ja) 2006-06-02 2007-06-01 肝細胞成長因子（ｈｇｆ）結合蛋白質
JP2010294222A Withdrawn JP2011072318A (ja) 2006-06-02 2010-12-28 肝細胞成長因子（ｈｇｆ）結合蛋白質
JP2012269474A Active JP5735476B2 (ja) 2006-06-02 2012-12-10 肝細胞成長因子（ｈｇｆ）結合蛋白質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010294222A Withdrawn JP2011072318A (ja) 2006-06-02 2010-12-28 肝細胞成長因子（ｈｇｆ）結合蛋白質
JP2012269474A Active JP5735476B2 (ja) 2006-06-02 2012-12-10 肝細胞成長因子（ｈｇｆ）結合蛋白質

Country Status (20)

Country Link
US (5) US7649083B2 (enExample)
EP (2) EP2361934A3 (enExample)
JP (3) JP4686634B2 (enExample)
KR (1) KR101196060B1 (enExample)
AR (1) AR061171A1 (enExample)
AT (1) ATE495195T1 (enExample)
AU (1) AU2007254942B2 (enExample)
BR (1) BRPI0712222B1 (enExample)
CA (1) CA2654025C (enExample)
CY (1) CY1111714T1 (enExample)
DE (1) DE602007011923D1 (enExample)
DK (1) DK2027156T3 (enExample)
IL (2) IL195037A (enExample)
MX (1) MX2008014829A (enExample)
NO (1) NO345476B1 (enExample)
NZ (1) NZ573818A (enExample)
PL (1) PL2027156T3 (enExample)
PT (1) PT2027156E (enExample)
SG (1) SG158112A1 (enExample)
WO (1) WO2007143090A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201319088A (zh) 2003-07-18 2013-05-16 Amgen Inc 對肝細胞生長因子具專一性之結合劑
AR061170A1 (es) 2006-06-02 2008-08-06 Aveo Pharmaceuticals Inc Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
PL2027156T3 (pl) * 2006-06-02 2011-06-30 Aveo Pharmaceuticals Inc Białka wiążące czynnik wzrostowy hapatocytów (HGF)
US20080233660A1 (en) * 2007-03-23 2008-09-25 Mu Bioteknik Ab Solid phase labeling method
EP3424529A1 (en) 2007-07-02 2019-01-09 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
SG186017A1 (en) 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
EP4588519A3 (en) * 2008-03-14 2025-10-15 Allergan, Inc. Immuno-based botulinum toxin serotype a activity assays
AU2009255305B2 (en) 2008-05-29 2014-10-30 Galaxy Biotech, Llc Monoclonal antibodies to basic fibroblast growth factor
MX2011000455A (es) 2008-11-07 2011-02-25 Galaxy Biotech Llc Anticuerpos monoclonales especificos al receptor 2 del factor de crecimiento de fibroblastos.
US20120052064A1 (en) 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
AU2011295919A1 (en) 2010-08-31 2013-03-07 Genentech, Inc. Biomarkers and methods of treatment
CA3027071A1 (en) 2011-01-14 2013-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
CN106167526A (zh) 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用
AU2012304362A1 (en) 2011-09-09 2014-03-06 Amgen Inc. Use of c-Met protein for predicting the efficacy of anti-hepatocyte growth factor ("HGF") antibodies in esophageal and gastric cancer patients
KR20140064971A (ko) 2011-09-19 2014-05-28 제넨테크, 인크. c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료
KR20150036603A (ko) 2012-07-13 2015-04-07 온코메드 파마슈티칼스, 인크. Rspo3 결합제 및 그의 용도
HK1211235A1 (en) 2013-02-22 2016-05-20 霍夫曼-拉罗奇有限公司 Methods of treating cancer and preventing drug resistance
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
US9062104B2 (en) 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
TW201438737A (zh) * 2013-03-14 2014-10-16 Alder Biopharmaceuticals Inc Ｈｇｆ抗體之治療用途
US9481725B2 (en) * 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
WO2014166029A1 (zh) * 2013-04-07 2014-10-16 永卓博济(上海)生物医药技术有限公司 针对表皮生长因子受体的抗体
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
KR20170005016A (ko) 2014-05-23 2017-01-11 제넨테크, 인크. MiT 바이오마커 및 그의 사용 방법
US20170247437A1 (en) * 2014-08-15 2017-08-31 Oncomed Pharmaceuticals, Inc. Rspo1 binding agents and uses thereof
TW201628648A (zh) 2014-09-16 2016-08-16 安可美德藥物股份有限公司 纖維變性疾病之治療
WO2017070567A1 (en) * 2015-10-21 2017-04-27 The Research Foundation For The State University Of New York Klebsiella pneumoniae antibodies and methods to treat klebsiella pneumoniae infections
JP2022543555A (ja) 2019-08-12 2022-10-13 インテアールエヌエー テクノロジーズ ビー．ヴイ． ｍｉＲＮＡ－１９３ａに関する新たな処置
AU2021227002A1 (en) 2020-02-28 2022-09-15 Interna Technologies B.V. miRNA-193a for promoting immunogenic cell death
WO2022042673A1 (zh) * 2020-08-28 2022-03-03 江苏恒瑞医药股份有限公司 用于降低异源多肽末端异质性的信号肽
MX2023012899A (es) 2021-05-05 2023-11-08 Immatics Biotechnologies Gmbh Polipeptidos de union a antigeno bma031 mejorados.

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
ATE249840T1 (de) 1991-12-13 2003-10-15 Xoma Corp Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
WO2001034650A1 (en) 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
US6881557B2 (en) * 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
TW201319088A (zh) 2003-07-18 2013-05-16 Amgen Inc 對肝細胞生長因子具專一性之結合劑
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
JP2008545753A (ja) 2005-06-02 2008-12-18 ギャラクシー バイオテック， エルエルシー 抗体で脳腫瘍を処置する方法
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
PL2027156T3 (pl) 2006-06-02 2011-06-30 Aveo Pharmaceuticals Inc Białka wiążące czynnik wzrostowy hapatocytów (HGF)
AR061170A1 (es) 2006-06-02 2008-08-06 Aveo Pharmaceuticals Inc Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
KR100829972B1 (ko) 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
KR100881825B1 (ko) * 2007-07-27 2009-02-03 주식회사 하이닉스반도체 반도체 소자 및 그 제조 방법

Also Published As

Publication number Publication date
IL195037A (en) 2015-08-31
WO2007143090A2 (en) 2007-12-13
BRPI0712222A2 (pt) 2012-01-10
SG158112A1 (en) 2010-01-29
US7649083B2 (en) 2010-01-19
AU2007254942A8 (en) 2009-02-05
ATE495195T1 (de) 2011-01-15
KR101196060B1 (ko) 2012-11-01
CA2654025A1 (en) 2007-12-13
NZ573818A (en) 2011-09-30
HK1129395A1 (en) 2009-11-27
BRPI0712222B1 (pt) 2021-10-13
IL195037A0 (en) 2011-08-01
EP2027156B1 (en) 2011-01-12
CY1111714T1 (el) 2015-10-07
EP2027156A2 (en) 2009-02-25
KR20090027226A (ko) 2009-03-16
NO20085421L (no) 2009-02-27
CA2654025C (en) 2016-08-02
PL2027156T3 (pl) 2011-06-30
US7943344B2 (en) 2011-05-17
US8273355B2 (en) 2012-09-25
EP2027156B9 (en) 2011-03-30
WO2007143090A3 (en) 2008-03-13
JP2011072318A (ja) 2011-04-14
EP2361934A3 (en) 2011-11-02
AR061171A1 (es) 2008-08-06
AU2007254942A2 (en) 2009-05-28
AU2007254942A1 (en) 2007-12-13
IL219654A0 (en) 2012-06-28
US20080108565A1 (en) 2008-05-08
JP2013090632A (ja) 2013-05-16
PT2027156E (pt) 2011-04-18
US8580930B2 (en) 2013-11-12
NO345476B1 (no) 2021-02-22
DE602007011923D1 (de) 2011-02-24
US20140178935A1 (en) 2014-06-26
US20100173362A1 (en) 2010-07-08
EP2361934A2 (en) 2011-08-31
US9096664B2 (en) 2015-08-04
JP2009539347A (ja) 2009-11-19
MX2008014829A (es) 2009-01-29
US20110229462A1 (en) 2011-09-22
US20130203963A1 (en) 2013-08-08
JP5735476B2 (ja) 2015-06-17
DK2027156T3 (da) 2011-04-26
AU2007254942B2 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
JP4686634B2 (ja) 肝細胞成長因子（ｈｇｆ）結合蛋白質
JP4560582B2 (ja) 肝細胞成長因子（ｈｇｆ）結合蛋白質
JP2009539347A5 (enExample)
JP5058261B2 (ja) 抗ミオスタチン抗体
US11014983B2 (en) Anti-Tim-3 antibodies, compositions comprising anti-Tim-3 antibodies and methods of making and using anti-Tim-3 antibodies
US20190330336A1 (en) Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
EP3087097B1 (en) Multifunctional antibodies binding to egfr and met
TW201525004A (zh) 結合前蛋白轉化酶枯草桿菌蛋白酶加工酶９型之人類抗原結合蛋白
KR20100049682A (ko) 안지오포이에틴-2 의 특이 결합제
CN118667012A (zh) Fcrn抗体及其使用方法
JP2019050822A (ja) ブラジキニンｂ１受容体リガンドに対する抗体
US8679497B2 (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
JP2023554326A (ja) Ｃｄ７３の抗原結合蛋白及びその使用
JP2024502758A (ja) Ｃｄ７３結合タンパク質及びその使用
ES2566343T3 (es) Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismos
BR112020019052A2 (pt) Anticorpo que se liga especificamente a gipr humano, proteína de fusão de glp-1, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica e uso da composição farmacêutica
ES2359176T3 (es) Proteínas de unión al factor de crecimiento de hepatocitos( hgf).
HK1129395B (en) Hepatocyte growth factor (hgf) binding proteins
HK1129394B (en) Hepatocyte growth factor (hgf) binding proteins
JP2025525348A (ja) λサブクラスの免疫グロブリン軽鎖の立体配座特異的エピトープを標的とするモノクローナル抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100617

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20100617

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20100721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101101

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101201

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101208

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20101228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110125

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110214

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140218

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4686634

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250